about
Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biologyClinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemiaIdentification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaTargeting NF-kappaB in Waldenstrom macroglobulinemiamicroRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemiaCXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.Engineered nanomedicine for myeloma and bone microenvironment targeting.The sialyltransferase ST3GAL6 influences homing and survival in multiple myelomaSDF-1 inhibition targets the bone marrow niche for cancer therapy.Pyk2 promotes tumor progression in multiple myelomaInvestigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model.Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma.Global epigenetic regulation of microRNAs in multiple myeloma.Metabolic signature identifies novel targets for drug resistance in multiple myeloma.Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.Novel agents in the treatment of Waldenström's macroglobulinemia.Candidate genes of Waldenström's macroglobulinemia: current evidence and research.CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.Role of proteasome inhibition in Waldenström's macroglobulinemia.Targeting the bone marrow in Waldenstrom macroglobulinemia.Bone marrow microenvironment in multiple myeloma progression.The bone marrow microenvironment in waldenstrom macroglobulinemia.Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model.Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination.Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.BM mesenchymal stromal cell–derived exosomes facilitatemultiple myeloma progression.Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia.Targeting vasculogenesis to prevent progression in multiple myeloma.Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomasEph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia
P50
Q21198869-FAF08FE3-3293-4760-863A-6951DCE1B2AAQ24634360-ACBF002D-B917-4EE1-BD1D-AA42B752BBB4Q28240713-8DF7D9B4-ED19-4792-B277-0373C8A23733Q28272373-0880E2DC-3837-4928-BC61-A9F5DC0B09EAQ28284121-1B65F276-CACF-4249-ACE9-1DD8343C613AQ30487339-E2D7A6B6-8143-4469-92F1-AE42AFA6FCE8Q30488936-0AF81F55-06B0-4F56-8368-ABD6883488F7Q33926003-89EC0967-1825-4FC2-B823-E191B9A16354Q34170367-08E51424-D43C-4E21-877E-B98F5B7F2D8BQ34324830-BE98EB3C-B61D-4B7B-B0BD-78885F0FC802Q34398382-B2A24B3E-EC94-457F-B93A-5D4E5D7342E0Q34551206-B5302271-ECA4-4743-87E0-03CD380C6964Q34778972-51789F74-16A4-4317-B143-B56FB73F3197Q35350129-2EB14A33-8888-445B-9FE0-070BC4922F4BQ35612105-9FF5D72D-D605-41AD-9D3A-53E95F596A29Q36352540-32E90095-893B-4318-8304-96AE342F400DQ36733492-CFD1BB75-97A7-4CEA-A91B-BD23A8FD6AD9Q36945183-F1E8972F-F983-485F-9E38-B87C5158C7CFQ37074275-631FCE92-C4B1-43AF-9B2A-5BA41D990935Q37127055-63445ADE-A517-4FC3-A51A-F55618137AE0Q37442368-9CAE5CF6-0C65-4EB4-BFCB-D2E1FE1A3432Q37950586-93D4FB32-1E05-4FE1-A0BF-5463EB083B70Q38055141-35FC3874-650E-4B00-8F42-7BD6C5AB9D06Q38095959-659D923D-FAA9-42E0-A2B2-3DDC2997763FQ38805629-131EC65E-CC93-48CC-A4E7-46A946204B4DQ38971845-0C7BBE26-1205-45D6-95D2-33EDFF861D26Q39585342-1F25AD68-76E5-4111-861C-9CFEBA9A3D86Q40001372-E1ACDCCF-6619-4B19-B98A-CA97B90387AAQ40083409-B206237F-6DFB-47A1-9117-11AD2E63F5DDQ40706695-785BEB9D-273D-495B-8E7A-23053ED832B6Q42081736-93DCB1A2-81FB-493C-AEB6-6EE50538E0B5Q42544052-F3B455A3-E5E3-4170-9911-A34B7626264CQ43651033-9CA3D5A6-4239-4941-A0A5-9F2B3E2C18F6Q46260424-365B0B33-B57F-4407-B9FE-1C08E7198144Q46266877-43F824FC-F0C8-4604-8D43-F3B838BC5BE7Q48232462-CC9A87EF-E204-447B-9F78-3DDF3C6AEC74Q52885536-9E67CF7E-D003-449C-B664-232302F63CB5Q53140789-B3029980-3068-4F78-9847-50855EA484FAQ61640851-3F96A467-01F0-4775-B6D3-49A505B95BB2Q82089040-659C25F1-A1DF-4636-947F-1F84B0154F17
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Antonio Sacco
@ast
Antonio Sacco
@en
Antonio Sacco
@es
Antonio Sacco
@nl
type
label
Antonio Sacco
@ast
Antonio Sacco
@en
Antonio Sacco
@es
Antonio Sacco
@nl
prefLabel
Antonio Sacco
@ast
Antonio Sacco
@en
Antonio Sacco
@es
Antonio Sacco
@nl
P1053
K-4681-2016
P106
P21
P31
P3829
P496
0000-0003-2945-9416